Compare NFG & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFG | PCVX |
|---|---|---|
| Founded | 1902 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 7.0B |
| IPO Year | 1998 | 2020 |
| Metric | NFG | PCVX |
|---|---|---|
| Price | $81.72 | $59.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $102.00 | $88.25 |
| AVG Volume (30 Days) | 675.5K | ★ 925.1K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | ★ 576.19 | N/A |
| EPS | ★ 6.01 | N/A |
| Revenue | ★ $2,277,541,000.00 | N/A |
| Revenue This Year | $15.04 | N/A |
| Revenue Next Year | $23.44 | N/A |
| P/E Ratio | $13.69 | ★ N/A |
| Revenue Growth | ★ 17.11 | N/A |
| 52 Week Low | $75.17 | $29.87 |
| 52 Week High | $97.06 | $65.00 |
| Indicator | NFG | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 52.41 | 61.02 |
| Support Level | $79.73 | $52.18 |
| Resistance Level | $83.31 | $62.54 |
| Average True Range (ATR) | 1.71 | 2.41 |
| MACD | -0.09 | 0.41 |
| Stochastic Oscillator | 55.75 | 91.75 |
National Fuel Gas Co is a diversified energy company involved in natural gas production, gathering, transportation, distribution, and marketing. It operates through three segments: Integrated Upstream and Gathering, Pipeline and Storage, and Utility. The majority of revenue comes from the Integrated Upstream and Gathering segment, which focuses on Seneca's natural gas exploration and development in the Appalachian region and Midstream operations supporting gas processing and gathering. The Pipeline and Storage segment transports and stores natural gas for customers in the northeastern United States and Canada, while the Utility segment supplies natural gas to retail customers in western New York and northwestern Pennsylvania. the company opeartes in United States.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.